Mobocertinib: Mechanism of action, clinical, and translational science
Abstract Epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations represent ~6%–12% of all EGFR‐mutated non‐small cell lung cancer (NSCLC) cases. First‐, second‐, and third‐generation tyrosine kinase inhibitors (TKIs) have limited clinical activity against EGFR ex20ins mutations...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-03-01
|
| Series: | Clinical and Translational Science |
| Online Access: | https://doi.org/10.1111/cts.13766 |